This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): aldesleukin, interleukin-2, IL-2
Description: Proleukin is a recombinant form of interleukin-2 for the treatment of metastatic renal cell carcinoma and metastatic melanoma.
As of 2006, revenues are no longer reported for Proleukin. As such, BioMedTracker no longer forecasts revenues.
Revenue splits for this drug are BioMedTracker estimates.
In July 1991, development of Proleukin was transferred to Chiron when the Company acquired Cetus. Chiron was then bought by Novartis in April 2006.
In January 2010, Prometheus Laboratories announced the execution of a commercialization agreement with Novartis under which Prometheus acquired exclusive rights to distribute, promote and sell Proleukin in the United States. Under the terms of the agreement, Novartis received an upfront fee and will receive royalties on net sales of Proleukin in the U.S. Novartis is also eligible to receive potential sales milestone payments. Prometheus will have the option to extend the initial six-year term on an annual basis for up to an additional six years. In addition, the companies will have an option to amend the agreement to include the rest of the...See full deal structure in Biomedtracker
Partners: Novartis AG
Pink Sheet In Brief: Chiron Proleukin
Additional information available to subscribers only: